|
Journal of Zhejiang University SCIENCE B
ISSN 1673-1581(Print), 1862-1783(Online), Monthly
2022 Vol.23 No.10 P.791-792
Cancer immunotherapy: an evolving paradigm
Abstract:
Key words:
References:
[1]ChenJ, ChenJ, WangL, 2022. Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor infiltrating immunocytes. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):812-822.
[2]FangL, QiH, WangP, et al., 2022. UPF1 increases amino acid levels and promotes cell proliferation in lung adenocarcinoma via the eIF2α-ATF4 axis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):863-875.
[3]GaoZR, LingXY, ShiCY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):823-843.
[4]GuTN, ZhuM, HuangH, et al., 2022. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):793-811.
[5]KongDL, YangTT, GengJ, et al., 2022. Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):876-880.
[6]QuL, HeXY, TangQ, et al., 2022. Iron metabolism, ferroptosis, and lncRNA in cancer: knowns and unknowns. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):844-862.
Open peer comments: Debate/Discuss/Question/Opinion
<1>
DOI:
10.1631/jzus.B2210001
CLC number:
Download Full Text:
Downloaded:
573
Clicked:
550
Cited:
0
On-line Access:
2022-10-12
Received:
2022-04-30
Revision Accepted:
2022-08-10
Crosschecked:
2022-10-13